Does autoimmunity play a part in the pathogenesis of glaucoma?

Progress in Retinal and Eye Research

Volumn 36, Issue , 2013, Pages 199-216

  Bell, Katharina ^a   Gramlich, Oliver W ^a   Von Thun Und Hohenstein Blaul, Nadine ^a   Beck, Sabine ^a   Funke, Sebastian ^a   Wilding, Corina ^a   Pfeiffer, Norbert ^a   Grus, Franz H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Animal model; Autoantibodies; Biomarker; Diagnosis; Glaucoma; Neuroprotection; Protective autoimmunity

Indexed keywords

CASPASE 3; CASPASE 8; CYTOCHROME C; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PERTUSSIS TOXIN; PROTEIN P53; VOLTAGE DEPENDENT ANION CHANNEL;

ANTERIOR EYE CHAMBER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; AQUEOUS HUMOR; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD RETINA BARRIER; CELL LOSS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DOWN REGULATION; GENE EXPRESSION REGULATION; GLAUCOMA; HOMEOSTASIS; HUMAN; HYDROSTATIC PRESSURE; IMMUNIZATION; IMMUNOREACTIVITY; IMMUNOREGULATION; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; NONHUMAN; OPTIC NERVE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA GANGLION CELL; REVIEW; UPREGULATION;

ANIMAL MODEL; AUTOANTIBODIES; BIOMARKER; DIAGNOSIS; GLAUCOMA; NEUROPROTECTION; PROTECTIVE AUTOIMMUNITY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; GLAUCOMA; HUMANS; RETINA;

EID: 84883219544     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.02.003     Document Type: Review

References (166)

1. Agar A., Li S., Agarwal N., Coroneo M.T., Hill M.A. Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res. 2006, 1086:191-200.
2. Alarcon-Segovia D., Ruiz-Arguelles A., Fishbein E. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature 1978, 271:67-69.
3. Allergan I. Press Releases on Memantine Trials 2010, Fourth Quarter Operating Results, Jan 30 2008. http://agn.client.shareholder.com/releasedetail.cfm%3fReleaseID%3d290764.
4. Anderson D.R., Drance S.M., Schulzer M. Natural history of normal-tension glaucoma. Ophthalmology 2001, 108:247-253.
5. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., Harley J.B. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N.Engl. J. Med. 2003, 349:1526-1533.
6. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol. Today 1991, 12:154-159.
7. Bacalini M.G., Tavolaro S., Peragine N., Marinelli M., Santangelo S., Del Giudice I., Mauro F.R., Di Maio V., Ricciardi M.R., Caiafa P., Chiaretti S., Foa R., Guarini A., Reale A. Asubset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. Exp. Hematol. 2012, 40:197-206. e191.
8. Badie B., Schartner J., Prabakaran S., Paul J., Vorpahl J. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J.Neuroimmunol 2001, 120:19-24.
9. Baltmr A., Duggan J., Nizari S., Salt T.E., Cordeiro M.F. Neuroprotection in glaucoma - is there a future role?. Exp. Eye Res. 2010, 91:554-566.
10. Bell K., Funke S., Pfeiffer N., Grus F.H. Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells. PLoS One 2012, 7:e46910.
11. Bell K., Wilding C., Pfeiffer N., Grus F.H. Down regulation of 14-3-3 Ab in glaucoma patients could lead to loss of protective effects. Invest. Ophthalmol. Vis. Sci. 2012, 53:6592.
12. Benetti R., Del Sal G., Monte M., Paroni G., Brancolini C., Schneider C. The death substrate Gas2 binds m-calpain and increases susceptibility to p53-dependent apoptosis. EMBO J. 2001, 20:2702-2714.
13. Bengtsson B., Leske M.C., Hyman L., Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 2007, 114:205-209.
14. Boato F., Hechler D., Rosenberger K., Ludecke D., Peters E.M., Nitsch R., Hendrix S. Interleukin-1 beta and neurotrophin-3 synergistically promote neurite growth invitro. J.Neuroinflammation 2011, 8:183.
15. Boehm N., Wolters D., Thiel U., Lossbrand U., Wiegel N., Pfeiffer N., Grus F.H. New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study. Brain Behav. Immun. 2012, 26:96-102.
16. Boltz-Nitulescu G., Bazin H., Spiegelberg H.L. Specificity of fc receptors for IgG2a, IgG1/IgG2b, and IgE on rat macrophages. J.Exp. Med. 1981, 154:374-384.
17. Caspi R.R. Ocular autoimmunity: the price of privilege?. Immunol. Rev. 2006, 213:23-35.
18. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. J.Autoimmun. 2010, 34:J276-J286.
19. Cheung W., Guo L., Cordeiro M.F. Neuroprotection in glaucoma: drug-based approaches. Optom. Vis. Sci. 2008, 85:406-416.
20. Chua J., Vania M., Cheung C.M., Ang M., Chee S.P., Yang H., Li J., Wong T.T. Expression profile of inflammatory cytokines in aqueous from glaucomatous eyes. Mol. Vis. 2012, 18:431-438.
21. Clarke R.M., Lyons A., O'Connell F., Deighan B.F., Barry C.E., Anyakoha N.G., Nicolaou A., Lynch M.A. Apivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain. J.Biol. Chem. 2008, 283:1808-1817.
22. Cousins S.W., Trattler W.B., Streilein J.W. Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye. Curr. Eye Res. 1991, 10:287-297.
23. Coutinho A., Kazatchkine M.D., Avrameas S. Natural autoantibodies. Curr. Opin. Immunol. 1995, 7:812-818.
24. Dalakas M.C. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998, 51:S2-S8.
25. Derecki N.C., Cardani A.N., Yang C.H., Quinnies K.M., Crihfield A., Lynch K.R., Kipnis J. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J.Exp. Med. 2010, 207:1067-1080.
26. Dielemans I., Vingerling J.R., Wolfs R.C., Hofman A., Grobbee D.E., de Jong P.T. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands. The Rotterdam Study. Ophthalmology 1994, 101:1851-1855.
27. Dodel R., Balakrishnan K., Keyvani K., Deuster O., Neff F., Andrei-Selmer L.C., Roskam S., Stuer C., Al-Abed Y., Noelker C., Balzer-Geldsetzer M., Oertel W., Du Y., Bacher M. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and invitro models of Alzheimer's disease. J.Neurosci. 2011, 31:5847-5854.
28. Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M., Oertel W. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010, 70:513-528.
29. Dreyer E.B., Zurakowski D., Schumer R.A., Podos S.M., Lipton S.A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 1996, 114:299-305.
30. Duane's O. Duane's Ophthalmology on DVD-ROM edition 2010. Clin. Exp. Optom. 2010, 94:506-507.
31. EGS Terminology and Guidelines for Glaucoma 2006, http://www.eugs.org, second ed.
32. Fellman R.L., Tezel G., Wax M.B. Effects of methotrexate treatment on serum immunoreactivity of a patient with normal-pressure glaucoma. Am. J. Ophthalmol. 1999, 127:724-725.
33. Fisher J., Levkovitch-Verbin H., Schori H., Yoles E., Butovsky O., Kaye J.F., Ben-Nun A., Schwartz M. Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J.Neurosci. 2001, 21:136-142.
34. Garcia-Valenzuela E., Shareef S., Walsh J., Sharma S.C. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp. Eye Res. 1995, 61:33-44.
35. Gardino A.K., Yaffe M.B. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin. Cell. Dev. Biol. 2011, 22:688-695.
36. Gelinas C., White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev. 2005, 19:1263-1268.
37. George J., Gilburd B., Shoenfeld Y. The emerging concept of pathogenic natural autoantibodies. Hum. Antibodies 1997, 8:70-75.
38. Gramlich O.W., Beck S., von Thun und Hohenstein-Blaul N., Boehm N., Ziegler A., Vetter J.M., Pfeiffer N., Grus F.H. Enhanced insight into the autoimmune component of glaucoma: IgG autoantibody accumulation and pro-inflammatory conditions in human glaucomatous retina. PLoS One 2013, 8(2):e57557. Epub 2013 Feb 25. 10.1371/journal.pone.0057557.
39. Graus Y.M., De Baets M.H. Myasthenia gravis: an autoimmune response against the acetylcholine receptor. Immunol. Res. 1993, 12:78-100.
40. Grus F.H., Joachim S.C., Bruns K., Lackner K.J., Pfeiffer N., Wax M.B. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest. Ophthalmol. Vis. Sci. 2006, 47:968-976.
41. Grus F.H., Joachim S.C., Hoffmann E.M., Pfeiffer N. Complex autoantibody repertoires in patients with glaucoma. Mol. Vis. 2004, 10:132-137.
42. Grus F.H., Joachim S.C., Pfeiffer N. Analysis of complex autoantibody repertoires by surface-enhanced laser desorption/ionization-time of flight mass spectrometry. Proteomics 2003, 3:957-961.
43. Grus F.H., Joachim S.C., Wuenschig D., Rieck J. Autoimmunity and glaucoma. J.Glaucoma 2008, 17:79-84.
44. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J.Dermatol. 2010, 37:42-53.
45. Hare W.A., WoldeMussie E., Weinreb R.N., Ton H., Ruiz G., Wijono M., Feldmann B., Zangwill L., Wheeler L. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest. Ophthalmol. Vis. Sci. 2004, 45:2640-2651.
46. Harman D. Aging: a theory based on free radical and radiation chemistry. J.Gerontol. 1956, 11:298-300.
47. Harris A., Ciulla T.A., Chung H.S., Martin B. Regulation of retinal and optic nerve blood flow. Arch. Ophthalmol. 1998, 116:1491-1495.
48. Hauben E., Butovsky O., Nevo U., Yoles E., Moalem G., Agranov E., Mor F., Leibowitz-Amit R., Pevsner E., Akselrod S., Neeman M., Cohen I.R., Schwartz M. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J.Neurosci. 2000, 20:6421-6430.
49. Hauben E., Gothilf A., Cohen A., Butovsky O., Nevo U., Smirnov I., Yoles E., Akselrod S., Schwartz M. Vaccination with dendritic cells pulsed with peptides of myelin basic protein promotes functional recovery from spinal cord injury. J.Neurosci. 2003, 23:8808-8819.
50. Healy S., Khan D.H., Davie J.R. Gene expression regulation through 14-3-3 interactions with histones and HDACs. Discov. Med. 2011, 11:349-358.
51. Heijl A., Bengtsson B., Hyman L., Leske M.C. Natural history of open-angle glaucoma. Ophthalmology 2009, 116:2271-2276.
52. Hueber W., Utz P.J., Robinson W.H. Autoantibodies in early arthritis: advances in diagnosis and prognostication. Clin. Exp. Rheumatol. 2003, 21:S59-S64.
53. Hughes B.W., Moro De Casillas M.L., Kaminski H.J. Pathophysiology of myasthenia gravis. Semin. Neurol. 2004, 24:21-30.
54. Ikeda Y., Maruyama I., Nakazawa M., Ohguro H. Clinical significance of serum antibody against neuron-specific enolase in glaucoma patients. Jpn. J. Ophthalmol. 2002, 46:13-17.
55. Jha P., Sohn J.H., Xu Q., Nishihori H., Wang Y., Nishihori S., Manickam B., Kaplan H.J., Bora P.S., Bora N.S. The complement system plays a critical role in the development of experimental autoimmune anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2006, 47:1030-1038.
56. Joachim S.C., Bruns K., Lackner K.J., Pfeiffer N., Grus F.H. Antibodies to alpha b-crystallin, vimentin, and heat shock protein 70 in aqueous humor of patients with normal tension glaucoma and IgG antibody patterns against retinal antigen in aqueous humor. Curr. Eye Res. 2007, 32:501-509.
57. Joachim S.C., Wuenschig D., Pfeiffer N., Grus F.H. IgG antibody patterns in aqueous humor of patients with primary open angle glaucoma and pseudoexfoliation glaucoma. Mol. Vis. 2007, 13:1573-1579.
58. Joachim S.C., Gramlich O.W., Laspas P., Schmid H., Beck S., von Pein H.D., Dick H.B., Pfeiffer N., Grus F.H. Retinal ganglion cell loss is accompanied by antibody depositions and increased levels of microglia after immunization with retinal antigens. PLoS One 2012, 7:e40616.
59. Joachim S.C., Grus F.H., Kraft D., White-Farrar K., Barnes G., Barbeck M., Ghanaati S., Cao S., Li B., Wax M.B. Complex antibody profile changes in an experimental autoimmune glaucoma animal model. Invest. Ophthalmol. Vis. Sci. 2009, 50:4734-4742.
60. Joachim S.C., Grus F.H., Pfeiffer N. Analysis of autoantibody repertoires in sera of patients with glaucoma. Eur. J. Ophthalmol. 2003, 13:752-758.
61. Joachim S.C., Pfeiffer N., Grus F.H. Autoantibodies in patients with glaucoma: a comparison of IgG serum antibodies against retinal, optic nerve, and optic nerve head antigens. Graefes Arch. Clin. Exp. Ophthalmol. 2005, 243:817-823.
62. Joachim S.C., Reichelt J., Berneiser S., Pfeiffer N., Grus F.H. Sera of glaucoma patients show autoantibodies against myelin basic protein and complex autoantibody profiles against human optic nerve antigens. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:573-580.
63. Joachim S.C., Wax M.B., Seidel P., Pfeiffer N., Grus F.H. Enhanced characterization of serum autoantibody reactivity following HSP 60 immunization in a rat model of experimental autoimmune glaucoma. Curr. Eye Res. 2010, 35:900-908.
64. Ju W.K., Kim K.Y., Lindsey J.D., Angert M., Patel A., Scott R.T., Liu Q., Crowston J.G., Ellisman M.H., Perkins G.A., Weinreb R.N. Elevated hydrostatic pressure triggers release of OPA1 and cytochrome C, and induces apoptotic cell death in differentiated RGC-5 cells. Mol. Vis. 2009, 15:120-134.
65. Kaplan H.J., Streilein J.W. Analysis of immunologic privilege within the anterior chamber of the eye. Transplant. Proc. 1977, 9:1193-1195.
66. Kaplan H.J., Streilein J.W. Immune response to immunization via the anterior chamber of the eye. II. An analysis of F1 lymphocyte-induced immune deviation. J.Immunol. 1978, 120:689-693.
67. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish R.K., Wilson M.R., Gordon M.O. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002, 120:701-713. Discussion 829-730.
68. Kaya Z., Afanasyeva M., Wang Y., Dohmen K.M., Schlichting J., Tretter T., Fairweather D., Holers V.M., Rose N.R. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2001, 2:739-745.
69. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N.Engl. J. Med. 2001, 345:747-755.
70. Kim S.U., de Vellis J. Microglia in health and disease. J.Neurosci. Res. 2005, 81:302-313.
71. Kipnis J., Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol. Med. 2002, 8:319-323.
72. Klein B.E., Klein R., Sponsel W.E., Franke T., Cantor L.B., Martone J., Menage M.J. Prevalence of glaucoma. The Beaver Dam eye study. Ophthalmology 1992, 99:1499-1504.
73. Kremmer S., Kreuzfelder E., Klein R., Bontke N., Henneberg-Quester K.B., Steuhl K.P., Grosse-Wilde H. Antiphosphatidylserine antibodies are elevated in normal tension glaucoma. Clin. Exp. Immunol. 2001, 125:211-215.
74. Kuehn M.H., Fingert J.H., Kwon Y.H. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol. Clin. North. Am. 2005, 18:383-395. (vi).
75. Kulberg A.Y. Immunoglobulins and antibodies. Russ. J. Immunol. 1999, 4:241-242.
76. Kumarswamy R., Chandna S. Putative partners in Bax mediated cytochrome-c release: ANT, CypD, VDAC or none of them?. Mitochondrion 2009, 9:1-8.
77. Laengle U.W., Markstein R., Cazaubon C., Roman D. Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release invitro of activated human monocytic leukemia cells. Jpn. J. Ophthalmol. 2009, 53:159-163.
78. Laengle U.W., Markstein R., Pralet D., Seewald W., Roman D. Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release invitro from activated rat mast cells. Exp. Eye Res. 2006, 83:1335-1339.
79. Laengle U.W., Markstein R., Pralet D., Seewald W., Roman D. Effects of latanoprost, timolol and GLC756, a novel dopamine D(2) agonist and D(1) antagonist on LTC(4) release after rat mast cell activation. Clin. Exp. Ophthalmol. 2007, 35:645-650.
80. Lambiase A., Mantelli F., Bonini S. Nerve growth factor eye drops to treat glaucoma. Drug News Perspect. 2010, 23:361-367.
81. Lane C., Leitch J., Tan X., Hadjati J., Bramson J.L., Wan Y. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 2004, 64:1509-1514.
82. Laspas P., Gramlich O.W., Muller H.D., Cuny C.S., Gottschling P.F., Pfeiffer N., Dick H.B., Joachim S.C., Grus F.H. Autoreactive antibodies and loss of retinal ganglion cells in rats induced by immunization with ocular antigens. Invest. Ophthalmol. Vis. Sci. 2011, 52:8835-8848.
83. Leske M.C., Connell A.M., Schachat A.P., Hyman L. The Barbados eye study. Prevalence of open angle glaucoma. Arch. Ophthalmol. 1994, 112:821-829.
84. Li W.H., Zhao J., Li H.Y., Liu H., Li A.L., Wang H.X., Wang J., He K., Liang B., Yu M., Shen B.F., Zhang X.M. Proteomics-based identification of autoantibodies in the sera of healthy Chinese individuals from Beijing. Proteomics 2006, 6:4781-4789.
85. Li X., Qian S.H., Sun X.H. Protection of autoimmunity induced by copolymer-1 on optic nerve: experiment with rat glaucoma models. Zhonghua Yi Xue Za Zhi 2008, 88:2152-2154.
86. Liu B., Neufeld A.H. Expression of nitric oxide synthase-2 in specific cells of human glaucomatous optic nerve head. Zhonghua Yan Ke Za Zhi 2001, 37:381-383.
87. Liu B., Neufeld A.H. Activation of epidermal growth factor receptor signals induction of nitric oxide synthase-2 in human optic nerve head astrocytes in glaucomatous optic neuropathy. Neurobiol. Dis. 2003, 13:109-123.
88. Loane D.J., Deighan B.F., Clarke R.M., Griffin R.J., Lynch A.M., Lynch M.A. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol. Aging 2009, 30:920-931.
89. Marta C.B., Bansal R., Pfeiffer S.E. Microglial Fc receptors mediate physiological changes resulting from antibody cross-linking of myelin oligodendrocyte glycoprotein. J.Neuroimmunol. 2008, 196:35-40.
90. Maruyama I., Ohguro H., Ikeda Y. Retinal ganglion cells recognized by serum autoantibody against gamma-enolase found in glaucoma patients. Invest. Ophthalmol. Vis. Sci. 2000, 41:1657-1665.
91. Massoner P., Lueking A., Goehler H., Hopfner A., Kowald A., Kugler K.G., Amersdorfer P., Horninger W., Bartsch G., Schulz-Knappe P., Klocker H. Serum-autoantibodies for discovery of prostate cancer specific biomarkers. Prostate 2012, 72:427-436.
92. Matus S., Burgos P.V., Bravo-Zehnder M., Kraft R., Porras O.H., Farias P., Barros L.F., Torrealba F., Massardo L., Jacobelli S., Gonzalez A. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J.Exp. Med. 2007, 204:3221-3234.
93. Medawar P.B. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 1948, 29:58-69.
94. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 1999, 5:49-55.
95. Mochizuki M., Sugita S., Ishikawa N., Watanabe T. Immunoregulation by aqueous humor. Cornea 2000, 19:S24-S25.
96. Mowatt G., Burr J.M., Cook J.A., Siddiqui M.A., Ramsay C., Fraser C., Azuara-Blanco A., Deeks J.J. Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis. Invest. Ophthalmol. Vis. Sci. 2008, 49:5373-5385.
97. Nagele E., Han M., Demarshall C., Belinka B., Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 2011, 6:e23112.
98. Neufeld A.H., Hernandez M.R., Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch. Ophthalmol. 1997, 115:497-503.
99. Nobrega A., Haury M., Grandien A., Malanchere E., Sundblad A., Coutinho A. Global analysis of antibody repertoires. II. Evidence for specificity, self-selection and the immunological "homunculus" of antibodies in normal serum. Eur. J. Immunol. 1993, 23:2851-2859.
100. Poletaev A., Osipenko L. General network of natural autoantibodies as immunological homunculus (Immunculus). Autoimmun. Rev. 2003, 2:264-271.
101. Poletaev A.B., Gnedenko B.B., Makarova A.A., Krasnopolsky V.I., Budykina T.S., Petrukhin V.A., Morozov S.G. Possible mechanisms of diabetic fetopathy. Hum. Antibodies 2000, 9:189-197.
102. Poletaev A.B., Morozov S.G., Gnedenko B.B., Zlunikin V.M., Korzhenevskey D.A. Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders. Autoimmunity 2000, 32:33-38.
103. Quigley H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 1996, 80:389-393.
104. Quigley H.A. Glaucoma. Lancet 2011, 377:1367-1377.
105. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006, 90:262-267.
106. Quigley H.A., Hohman R.M., Addicks E.M., Massof R.W., Green W.R. Morphologic changes in the lamina cribrosa correlated with neural loss in open-angle glaucoma. Am. J. Ophthalmol. 1983, 95:673-691.
107. Quintana F.J., Farez M.F., Viglietta V., Iglesias A.H., Merbl Y., Izquierdo G., Lucas M., Basso A.S., Khoury S.J., Lucchinetti C.F., Cohen I.R., Weiner H.L. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18889-18894.
108. Rajagopalan S., Sade R.S., Townsley F.M., Fersht A.R. Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoforms. Nucleic Acids Res. 2010, 38:893-906.
109. Reichelt J., Joachim S.C., Pfeiffer N., Grus F.H. Analysis of autoantibodies against human retinal antigens in sera of patients with glaucoma and ocular hypertension. Curr. Eye Res. 2008, 33:253-261.
110. Rudnicka A.R., Mt-Isa S., Owen C.G., Cook D.G., Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest. Ophthalmol. Vis. Sci. 2006, 47:4254-4261.
111. Schori H., Yoles E., Schwartz M. T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system. J.Neuroimmunol 2001, 119:199-204.
112. Schwartz M. Physiological approaches to neuroprotection. boosting of protective autoimmunity. Surv. Ophthalmol. 2001, 45(Suppl. 3):S256-S260. Discussion S273-256.
113. Schwartz M. Protective autoimmunity as a T-cell response to central nervous system trauma: prospects for therapeutic vaccines. Prog. Neurobiol. 2001, 65:489-496.
114. Schwartz M. Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all?. J.Glaucoma 2005, 14:321-323.
115. Schwartz M., Kipnis J. Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol. Med. 2001, 7:252-258.
116. Schwartz M., London A. Immune maintenance in glaucoma: boosting the body's own neuroprotective potential. J.Ocul. Biol. Dis. Infor 2009, 2:73-77.
117. Schwartz M., London A., Shechter R. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: the role of innate immunity. Neuroscience 2009, 158:1133-1142.
118. Shazly T.A., Aljajeh M., Latina M.A. Autoimmune basis of glaucoma. Semin. Ophthalmol. 2011, 26:278-281.
119. Shmerling R.H. Autoantibodies in systemic lupus erythematosus-there before you know it. N.Engl. J. Med. 2003, 349:1499-1500.
120. Shoenfeld Y., Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum. 2005, 52:2599-2606.
121. Shoshan-Barmatz V., De Pinto V., Zweckstetter M., Raviv Z., Keinan N., Arbel N. VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol. Aspects Med. 2010, 31:227-285.
122. Simpson E. Ahistorical perspective on immunological privilege. Immunol. Rev. 2006, 213:12-22.
123. Sluchanko N.N., Gusev N.B. 14-3-3 proteins and regulation of cytoskeleton. Biochemistry (Mosc) 2010, 75:1528-1546.
124. Sommer A., Tielsch J.M., Katz J., Quigley H.A., Gottsch J.D., Javitt J., Singh K. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol. 1991, 109:1090-1095.
125. Song Q., Liu G., Hu S., Zhang Y., Tao Y., Han Y., Zeng H., Huang W., Li F., Chen P., Zhu J., Hu C., Zhang S., Li Y., Zhu H., Wu L. Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. J.Proteome Res. 2010, 9:30-39.
126. Streilein J.W. Unraveling immune privilege. Science 1995, 270:1158-1159.
127. Streilein J.W. Immunologic privilege of the eye. Springer Semin. Immunopathol. 1999, 21:95-111.
128. Sutter A., Hekmat A., Luckenbach G.A. Antibody-mediated tumor cytotoxicity of microglia. Pathobiology 1991, 59:254-258.
129. Takahashi A., Masuda A., Sun M., Centonze V.E., Herman B. Oxidative stress-induced apoptosis is associated with alterations in mitochondrial caspase activity and Bcl-2-dependent alterations in mitochondrial pH (pHm). Brain Res. Bull. 2004, 62:497-504.
130. Tanaka T., Narazaki M., Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011, 585:3699-3709.
131. Tatton W.G., Chalmers-Redman R.M., Sud A., Podos S.M., Mittag T.W. Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma?. Surv. Ophthalmol. 2001, 45(Suppl. 3):S277-S283. Discussion S295-276.
132. Taylor A.W., Streilein J.W., Cousins S.W. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr. Eye Res. 1992, 11:1199-1206.
133. Teitelbaum D., Fridkis-Hareli M., Arnon R., Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J.Neuroimmunol 1996, 64:209-217.
134. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1:242-248.
135. Terenyi N., Prechl J., Erdei A. The role of the complement system in the pathogenesis of experimental autoimmune encephalomyelitis and multiple sclerosis. Adv. Exp. Med. Biol. 2006, 586:177-188.
136. Terzoglou A.G., Routsias J.G., Avrameas S., Moutsopoulos H.M., Tzioufas A.G. Preferential recognition of the phosphorylated major linear B-cell epitope of La/SSB 349-368 aa by anti-La/SSB autoantibodies from patients with systemic autoimmune diseases. Clin. Exp. Immunol. 2006, 144:432-439.
137. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res. 2006, 25:490-513.
138. Tezel G. The immune response in glaucoma: a perspective on the roles of oxidative stress. Exp. Eye Res. 2011, 93:178-186.
139. Tezel G., Edward D.P., Wax M.B. Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Arch. Ophthalmol. 1999, 117:917-924.
140. Tezel G., Hernandez R., Wax M.B. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch. Ophthalmol. 2000, 118:511-518.
141. Tezel G., Li L.Y., Patil R.V., Wax M.B. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest. Ophthalmol. Vis. Sci. 2001, 42:1787-1794.
142. Tezel G., Seigel G.M., Wax M.B. Autoantibodies to small heat shock proteins in glaucoma. Invest. Ophthalmol. Vis. Sci. 1998, 39:2277-2287.
143. Tezel G., Wax M.B. The mechanisms of hsp27 antibody-mediated apoptosis in retinal neuronal cells. J.Neurosci. 2000, 20:3552-3562.
144. Tezel G., Wax M.B. Glaucoma. Chem. Immunol. Allergy 2007, 92:221-227.
145. Tezel G., Yang X., Luo C., Kain A.D., Powell D.W., Kuehn M.H., Kaplan H.J. Oxidative stress and the regulation of complement activation in human glaucoma. Invest. Ophthalmol. Vis. Sci. 2010, 51:5071-5082.
146. Tielsch J.M., Sommer A., Katz J., Royall R.M., Quigley H.A., Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. Jama 1991, 266:369-374.
147. Troost A., Grunz C., Troost R., Grus F.H., Pfeiffer N., Schwenn O. Agreement between clinical evaluation, Heidelberg-Retina-Tomograph (HRT) and Nerve Fiber Analyzer (GDx) in glaucoma diagnosis. Klin Monbl Augenheilkd 2004, 221:757-761.
148. Ulvestad E., Williams K., Matre R., Nyland H., Olivier A., Antel J. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets. J.Neuropathol. Exp. Neurol. 1994, 53:27-36.
149. van Dooremaal J.C. Die Entwicklung der in fremden Grund versetzten lebenden Geweba. Albrecht von Graefes Arch. Opthalmol. 1873, 19:358-373.
150. Vaseva A.V., Moll U.M. The mitochondrial p53 pathway. Biochim. Biophys. Acta 2009, 1787:414-420.
151. Wax M.B. Is there a role for the immune system in glaucomatous optic neuropathy?. Curr. Opin. Ophthalmol. 2000, 11:145-150.
152. Wax M.B. The case for autoimmunity in glaucoma. Exp. Eye Res. 2011, 93:187-190.
153. Wax M.B., Barrett D.A., Pestronk A. Increased incidence of paraproteinemia and autoantibodies in patients with normal-pressure glaucoma. Am. J. Ophthalmol. 1994, 117:561-568.
154. Wax M.B., Tezel G., Edward P.D. Clinical and ocular histopathological findings in a patient with normal-pressure glaucoma. Arch. Ophthalmol. 1998, 116:993-1001.
155. Wax M.B., Tezel G., Saito I., Gupta R.S., Harley J.B., Li Z., Romano C. Anti-Ro/SS-A positivity and heat shock protein antibodies in patients with normal-pressure glaucoma. Am. J. Ophthalmol. 1998, 125:145-157.
156. Wax M.B., Tezel G., Yang J., Patil R., Sappington R., Calkins D. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cells via a FAS/FAS-ligand pathway. Invest. Ophthalmol. Vis. Sci. 2006, 47:1828.
157. Weiner H.L. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3333-3335.
158. Yanagi M., Kawasaki R., Wang J.J., Wong T.Y., Crowston J., Kiuchi Y. Vascular risk factors in glaucoma: a review. Clin. Exp. Ophthalmol. 2011, 39:252-258.
159. Yanase K., Smith R.M., Puccetti A., Jarett L., Madaio M.P. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J.Clin. Invest. 1997, 100:25-31.
160. Yang J., Tezel G., Patil R.V., Romano C., Wax M.B. Serum autoantibody against glutathione S-transferase in patients with glaucoma. Invest. Ophthalmol. Vis. Sci. 2001, 42:1273-1276.
161. Yang X., Luo C., Cai J., Pierce W.M., Tezel G. Phosphorylation-dependent interaction with 14-3-3 in the regulation of bad trafficking in retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2008, 49:2483-2494.
162. Yang X., Luo C., Cai J., Powell D.W., Yu D., Kuehn M.H., Tezel G. Neurodegenerative and inflammatory pathway components linked to TNF-alpha/TNFR1 signaling in the glaucomatous human retina. Invest. Ophthalmol. Vis. Sci. 2011, 52:8442-8454.
163. Zhou R., Caspi R.R. Ocular Immune Privilege 2010, F1000 Biol Rep. 2.
164. Zhou R., Horai R., Mattapallil M.J., Caspi R.R. Anew look at immune privilege of the eye: dual role for the vision-related molecule retinoic acid. J.Immunol. 2011, 187:4170-4177.
165. Zimmermann C.W., Eblen F. Repertoires of autoantibodies against homologous eye muscle in ocular and generalized myasthenia gravis differ. Clin. Investig. 1993, 71:445-451.
166. Zimmermann C.W., Weiss G. Antibodies not directed against the acetylcholine receptor in myasthenia gravis. An immunoblot study. J.Neuroimmunol. 1987, 16:225-236.